|
|
|
|
| AI and machine learning are the buzzwords of the decade, often accompanied by lofty promises — but what do they really mean for biopharma? How can these technologies be adopted to improve biomanufacturing processes, testing, and quality? Join Bioprocess Online Live for an exploration into the practical applications of AI/ML in biomanufacturing, its barriers to adoption, and how regulators can help standardize use across the industry. Registration is free thanks to the support of Atum Bio. |
|
|
|
|
A conversation with John Stubenrauch and Sam Deutsch, Nutcracker Therapeutics | Nutcracker's unique approach to scaling up to clinical manufacturing — which brings unique challenges compared to traditional biologics — relies on microfluidics. |
|
|
|
|
|
|
|
|
|
|
By Matthew Pillar, Editor, Bioprocess Online
| Where there is therapeutic demand, the industry will build capacity. But with ADCs, cytotoxic payloads and a fragmented contract manufacturing landscape make the path to clinical and commercial supply dauntingly complicated. Here's how the ADC manufacturing market is shaping up, and how it might ultimately shake out. |
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
.png)
